2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
pembrolizumab
1033
Carboplatin
971
Paclitaxel
942
Gemcitabine
799
Cisplatin
757
Docetaxel
698
Bevacizumab
637
Nivolumab
520
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
473
Fluorouracil
425
Dexamethasone
410
Rituximab
391
Oxaliplatin
352
Injections
347
Trastuzumab
313
atezolizumab
312
Cetuximab
291
Leucovorin
290
Irinotecan
271
130-nm albumin-bound paclitaxel
257
Prednisone
251
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
219
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
ceftolozane, tazobactam drug combination
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn